An Innovative Risk-Reducing Approach to Postmastectomy Radiation Delivery after Autologous Breast Reconstruction. by Piper, Merisa L et al.
UCSF
UC San Francisco Previously Published Works
Title
An Innovative Risk-Reducing Approach to Postmastectomy Radiation Delivery after 
Autologous Breast Reconstruction.
Permalink
https://escholarship.org/uc/item/1bf9h23r
Journal
Plastic and Reconstructive Surgery Global Open, 5(4)
ISSN
2169-7574
Authors
Piper, Merisa L
Evangelista, Maristella
Amara, Dominic
et al.
Publication Date
2017-04-25
DOI
10.1097/GOX.0000000000001265
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
 www.PRSGlobalOpen.com 1
The increasing use of total skin-sparing mastecto-my and nipple-sparing mastectomy in the United States has led to higher rates of mastectomy for 
treating and preventing breast cancer, as these tech-
niques offer improved aesthetic outcomes.1 A corre-
sponding rise in immediate breast reconstruction has 
paralleled this trend. Autologous breast reconstruction 
is a popular option given its excellent aesthetic results2–4 
and positive patient reported and clinical outcomes.4–6 
After mastectomy, many women require radiation ther-
apy to complete their cancer treatment, as a way to 
decrease locoregional recurrence.7–9 However, there is 
little consensus among radiation oncologists regarding 
the optimal delivery fields and dosages of postmastec-
tomy radiotherapy (PMRT) for the many women who 
undergo immediate autologous tissue-based recon-
struction.10–13
There is conflicting evidence about the ability of au-
tologous flaps to tolerate PMRT.14–20 Radiation therapy has 
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Introduction: Postmastectomy radiation therapy (PMRT) has known deleterious 
side effects in immediate autologous breast reconstruction. However, plastic sur-
geons are rarely involved in PMRT planning. Our institution has adopted a custom 
bolus approach for all patients receiving PMRT. This offers uniform distribution 
of standard radiation doses, thereby minimizing radiation-induced changes while 
maintaining oncologic safety. We present our 8-year experience with the custom 
bolus approach for PMRT delivery in immediate autologous breast reconstruction.
Methods: All immediate autologous breast reconstruction patients requiring PMRT 
after 2006 were treated with the custom bolus approach. Retrospective chart review 
was performed to compare the postirradiation complications, reconstruction out-
comes, and oncologic outcomes of these patients with those of previous patients 
at our institution who underwent standard bolus, and to historical controls from 
peer-reviewed literature.
Results: Over the past 10 years, of the 29 patients who received PMRT, 10 were 
treated with custom bolus. Custom bolus resulted in fewer radiation-induced skin 
changes and less skin tethering/fibrosis than standard bolus (0% vs 10% and 20% 
vs 35%, respectively), and less volume loss and contour deformities compared with 
historical controls (10% vs 22.8% and 10% vs 30.7%, respectively).
Conclusions: Custom bolus PMRT minimizes radiation delivery to the internal mam-
mary vessels, anastomoses, and skin; uniformly doses the surgical incision; and provides 
the necessary radiation dose to prevent recurrence. Because custom bolus PMRT may 
reduce the deleterious effects of radiation on reconstructive outcomes while maintain-
ing safe oncologic results, we encourage all plastic surgeons to collaborate with radia-
tion oncologists to consider this technique. (Plast Reconstr Surg Glob Open 2017;5:e1265; 
doi: 10.1097/GOX.0000000000001265; Published online 25 April 2017.)
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numerous potential deleterious effects on autologous tis-
sue flaps, and on the appearance and feel of the overall 
reconstruction. These include mild to severe erythema, hy-
perpigmentation, desquamation, fat necrosis, volume loss, 
fibrosis, flap contracture, and vascular thrombosis.18,20–25 As 
a result, irradiation of the flap may result in breast asymme-
try and an inferior overall aesthetic outcome.18,25–27
Despite the significant impact of radiation on autolo-
gous reconstruction, plastic surgeons are seldom involved 
in the decision-making process regarding radiation ther-
apy delivery. At our institution, plastic surgeons always 
maintain an open dialogue with radiation oncologists 
for radiation planning and delivery so as to optimize out-
comes and minimize radiation’s deleterious effects.
In this study, we present our experience with custom 
bolus PMRT, used to minimize deleterious effects to the 
reconstructed autologous breast mound. With standard 
bolus techniques, air gaps can lead to dose inhomogeneity 
that may lead to “hot spots,” thus resulting in overdoses of 
radiation to the skin in those areas. Custom bolus PMRT 
improves dose homogeneity involving the skin and subcu-
taneous tissues by conforming to the individual’s contour, 
thereby leading to fewer complications.28 Though it has 
been shown to be effective in prior literature,28 radiation 
oncologists do not widely use custom bolus.12 This may be 
explained by the initial time investment of designing the 
mold and planning the radiation delivery. At our institu-
tion, we have adopted custom bolus as the standard of care 
for all patients receiving PMRT. The following details our 
clinical outcomes over the past 8 years and compares them 
with outcomes before adoption of custom bolus, and with 
outcomes presented in peer-reviewed literature.
METHODS
Patient Selection
We reviewed the records of all patients with breast can-
cer who underwent mastectomy with immediate autolo-
gous reconstruction at our institution from 2005 to 2014. 
A total of 157 patients (226 breasts) were identified. Of 
these, 29 patients received PMRT, including 10 treated us-
ing our customized approach. Charts were retrospectively 
reviewed for patient demographics, operative reports, and 
radiation therapy details. Medical records of all included 
patients were reviewed in 2015 to ensure no complications 
were missed. This study was approved by the University 
of California, San Francisco Committee on Human Re-
search.
Surgical Technique
All patients had modified-radical, skin-sparing, or to-
tal skin-sparing mastectomy (complete nipple/areolar 
external skin preservation and internal inversion of the 
nipple with aggressive excision of all nipple parenchyma 
to the dermal junction). Incisions used for total skin-
sparing mastectomy included inframammary, superior 
periareolar, and other incisions (lateral, radial, and inci-
sions that incorporated prior breast surgery scars). Au-
tologous breast reconstruction options included pedicled 
transverse rectus abdominis myocutaneous (TRAM) flap, 
muscle-sparing TRAM free flap, or deep inferior epigas-
tric perforator free flap.
Radiation Therapy
Radiation was delivered to the reconstructed autolo-
gous breast in 29 patients. After 2006, 10 patients received 
our custom bolus method by a single radiation oncolo-
gist (BF), whereas the remaining 19 patients received the 
standard bolus method. The custom bolus uses perforated 
Aquaplast and a nearly tissue-equivalent wax (Kindt-Col-
lins, Cleveland, OH). First, perforated Aquaplast is heated 
and stretched over the reconstructed chest wall. Tissue 
equivalent wax is then heated and strips are placed over 
the Aquaplast. As the wax cools, it hardens and conforms 
to the irregular contours of the chest wall (Fig. 1). Total 
time for creation of the Aquaplast mold is 15 minutes, and 
materials’ cost is $100 per patient. This wax cast retains its 
molded shape, allowing for easy application throughout 
the duration of treatment, thus minimizing air gaps and 
consequently dose inhomogeneity.28
Fig. 1. Fabrication of custom bolus using perforated Aquaplast (A), which is then covered by tissue-
equivalent wax (B) to form a hard cast contoured to the irregularities of the reconstructed chest wall.
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The custom bolus radiation regimen consisted of op-
posed tangential fields to the breast using 6-MV or 6/18-
MV photons with the field-in-field technique. Five hours 
of labor are typically needed per patient to construct the 
bolus. The cost of constructing the bolus depends on 
the salary of the person doing the construction, who is 
typically a technician. A custom bolus of 5 mm was used 
every-other-day with 3 mm over central or inframammary 
surgical scars. No boost to the mastectomy scar was given. 
Prophylactic radiation was not delivered to the internal 
mammary nodes unless patients had positive nodes docu-
mented by imaging or biopsy (Fig. 2).
The location of the internal mammary anastomosis 
was marked intraoperatively with clips, so the radiation 
oncologist could limit radiation to this area if possible 
without compromising coverage of the targeted regions. 
Patients received radiation to the supraclavicular region 
if 4 or more positive axillary nodes were identified. On 
non-bolus days (treatment given but no bolus used), film 
dosimeter readings were obtained, and on bolus days, op-
tical luminescent dosimeter readings were used to assess 
adequacy of the radiation plan.
Total radiation delivered was 5000–5040 cGy adminis-
tered in 180–200 cGy fractions per day for 5 days a week 
over a 5- to 6-week period. Standard fractionation was 
used. Surface dose was measured with film dosimeters on 
non-bolus days and optical luminescent dosimeters on 
bolus days to confirm that the superficial doses being de-
livered were adequate to control microscopic disease. No 
patients with gross disease were treated.
Outcomes
Retrospective chart review was performed, and the fol-
lowing complications were recorded: infection, wound de-
hiscence, nipple necrosis, skin flap necrosis, unplanned 
return to the operating room, and flap loss. Additionally, 
all charts were reviewed for radiation-specific complica-
tions, namely skin changes, fat necrosis, breast asymme-
try/volume loss, pain, and severe scarring and tethering. 
Infection was divided into those treated with oral versus 
those treated with intravenous antibiotics. We defined 
nipple necrosis as either partial or complete loss of the 
nipple areola complex skin. Mastectomy skin flap necrosis 
was defined as either partial- or full-thickness loss of breast 
skin. Local and distant cancer recurrences after radiation 
therapy were also recorded.
We used the Radiation Therapy Oncology Group 
(RTOG) and European Organization for Research and 
Treatment of Cancer (EORTC) acute radiation toxic-
ity grading system for evaluating radiation-induced skin 
changes.29 Skin changes were documented if they were 
considered grade III (confluent, moist desquamation oth-
er than skin folds, pitting edema) or higher. Fat necrosis 
was defined as clinically significant fat necrosis, which was 
Fig. 2. A, isodose curves for a 55-year-old woman with stage iiA carcinoma of the left breast and a positive sentinel node. She received 
PMRT to the left DiEP reconstructed breast and supraclavicular region. The vascular clips at the DiEP anastomosis are outlined in yellow. 
Some of the clips are in the radiation field, outlined in red, with a dose of 50 gy. Although the anastomosis was not completely excluded 
from radiation, the dose was much lower than that prescribed for the tumor. B, isodose curves for a 42-year-old woman with stage iV 
carcinoma of the left breast and extensive recurrent axillary disease. She received PMRT to the left DiEP reconstructed breast, axilla, and 
supraclavicular area. The vascular clips of the DiEP anastomosis are outlined in red. The anastomosis was outside the higher doses of the 
radiation fields.
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palpable during postoperative evaluation and often re-
quired surgical excision.
The outcomes from the subset of 10 patients (10 
breasts) treated with custom bolus were compared with 
those of the 19 additional patients (20 breasts) at our insti-
tution who were treated with standard PMRT. As a way to 
qualify our data against other institutions, we performed 
a literature search using PubMed to compare our results 
against historical controls. We sought out articles that 
specifically evaluated outcomes of postmastectomy radia-
tion therapy on autologous breast reconstruction. Search 
terms included “autologous tissue reconstruction,” “breast 
reconstruction,” “postmastectomy radiation therapy,” “ad-
juvant radiation therapy,” and a combination of the above. 
References from selected articles were reviewed to identify 
additional articles. Articles were excluded if they did not 
include pertinent complications, did not stratify by meth-
od of reconstruction, or had less than 1 year of follow-up. 
If multiple studies were published from the same group, 
only the most recent study was used. Ultimately 11 articles 
were used for comparison.18,22,23,25,26,30–35
RESULTS
Patient and Treatment Characteristics
Between 2005 and 2015, 157 patients (226 breasts) 
underwent immediate autologous tissue breast recon-
struction after mastectomy at our institution. Of these, 
29 patients (18.5%) received PMRT, and 10 patients 
(34.5%) of these were treated with our customized ap-
proach (Fig. 3). Patients were similar with regard to age, 
body mass index, smoking status, medical comorbidities, 
chemotherapy, previous breast radiation, clinical stage, 
pathologic stage, or estrogen receptor/progesterone re-
ceptor status (Table 1). However, notably more patients 
in the custom bolus group received hormone therapy and 
were HER2+. Most patients (83.3%) had pedicled TRAM 
reconstruction (Table 2).
Outcomes
We found clinically that patients who had custom bolus 
trended toward lower rates of nipple loss, fewer radiation-
induced skin changes, and decreased excessive scarring 
compared with patients who had standard bolus radiation 
delivery (Table 3). In terms of early complications, custom 
bolus patients in our study trended to lower clinical rates 
of skin flap necrosis and delayed wound healing. In terms 
of late complications, custom bolus patients in our study 
showed clinical trends to less volume loss and contour de-
formity.
Mean follow-up for the custom bolus cohort was 62.8 
months, with the range from 14.2 to 101.2 months. Mean 
follow-up for the standard bolus cohort was 59.9 months, 
with the range from 9.4 to 101.4 months. No patients had 
local recurrence in the custom bolus group. One patient 
had local recurrence in the standard bolus group at the 
level of the skin, and was treated with re-excision. One 
patient in the custom bolus cohort developed metastatic 
disease, and 2 patients in the standard bolus group de-
veloped metastatic disease. Two of these patients are still 
alive, and 1 was lost to follow-up.
Comparison of radiation-specific complications across 
the 11 articles from our literature review indicated sig-
nificant variability in reported outcomes (Table 4). Flap 
loss was the most frequently reported outcome, and rates 
were low (0%–1.6%) in all studies. Three studies22,26,31 pre-
dominantly used pedicled TRAM flaps for reconstruction, 
similar to our institution. Of those 3 studies, only 1 study26 
reported fat necrosis rates, and these were comparable 
with our rates. Two studies22,31 reported radiation-induced 
skin changes in 9.1% and 0% of patients, which were also 
comparable with our rates (10% in standard bolus, 0% in 
custom bolus).
Overall, volume loss, delayed wound healing, infec-
tion, and radiation-induced skin changes were reported 
in only 5 of the 11 studies, excessive scarring was reported 
in 2 of the 11 studies, and nipple necrosis was reported in 
only 1 study. These complications are often dramatically 
affected by radiation therapy, yet no study consistently re-
ported them.
DISCUSSION
Traditionally, the decision to undergo immediate versus 
delayed reconstruction is strongly influenced by the need 
for PMRT. The 2014 ASPS Clinical Practice Guidelines 
cite that although evidence is limited, radiation acts as a 
Fig. 3. Woman who had bilateral DiEP breast reconstructions underwent PMRT using custom bolus. A, 
One week after radiation therapy completed. B, nine weeks after radiation therapy completed.
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confounding factor in the timing of expander/implant re-
construction.36 The decision to perform immediate versus 
delayed autologous reconstruction in the setting of PMRT 
is even less-explored. PMRT is often the reason that many 
institutions delay autologous reconstruction,37 even though 
PMRT has not been shown to significantly affect the revi-
sion rate for immediate autologous reconstruction.23 As 
patients have been shown to prefer and benefit psychologi-
cally from immediate reconstruction,37–40 further advances 
in PMRT (along with better coordination of care among 
plastic surgeons and radiation oncologists) may help sim-
plify the decision about whether to perform immediate au-
tologous reconstruction in this setting. Through this open 
dialogue, including anticipated radiation delivery dosages 
and length of treatment, reconstructive surgeons may be 
able to tailor individual decisions for each patient as to 
their best timing for reconstruction.
Surgeons and radiation oncologists differ in their 
awareness and attitudes toward PMRT, with most radia-
tion oncologists reporting lack of early participation in 
treatment planning for breast cancer patients.41 Though 
it can have major consequences on reconstructive out-
comes, PMRT is often left to the jurisdiction of the radia-
tion oncology team alone. Many radiation oncologists are 
not considering reconstructive procedures or flap physi-
ology/anatomy when they plan and implement radiation 
delivery,10 and thus may choose more aggressive protocols.
Radiation protocols vary widely between institutions and 
providers. The use of bolus is considered standard for post-
mastectomy radiation to prevent underdosing of the super-
ficial tissues, and most major cancer centers in the United 
States use bolus.42 Unfortunately, most papers do not report 
the exact radiation protocols used. This makes it challeng-
ing to compare outcomes after radiation between different 
institutions, which is one of the challenges we faced when 
comparing our 2 groups with historical controls.
Additionally, plastic surgeons are often unaware and 
uninvolved in the process. We think it is important for 
plastic surgeons and radiation oncologists to work collab-
oratively. Coordinating care early enables the plastic sur-
geon to gain a better understanding of the steps involved 
in developing a radiation plan, and the radiation oncolo-
gist to adapt the radiation protocol for future reconstruc-
tion. Therefore, great effort should be made to improve 
Table 1. Patient and Tumor Characteristics of Custom and Standard Bolus Patients
 
Custom Bolus 
(n = 10)
Standard Bolus 
(n = 20)
P-value
(Custom Bolus vs  
Standard Bolus)*
Mirzabeigi et al.
(n = 127)
P-value
(Custom Bolus vs 
Mirzabeigi et al.)*
Mean follow-up months 61.4 59.9 0.91† 23.2 —
Mean age (SD) 51.5 (6.0) 52.8 (8.1) 0.66† 47.1 (8.5) 0.15†
Mean BMI (SD) 28.9 (4.4) 28.4 (3.4) 0.73† 28.2 (5.7) 0.71†
Comorbidities      
  Diabetes, n (%) 1 (10) 2 (10) 1.0 8 (6.3) 0.51
  PVD, n (%) 0 0 1.0 1 (0.9) 1
  CAD, n (%) 0 0 1.0 1 (0.9) 1
  Hypertension, n (%) 4 (40) 2 (10) 0.14 29 (22.8) 0.25
  COPD, n (%) 0 0 1.0 1 (0.9) 1
  Hypercholesterolemia, n (%) 1 (10) 1 (5) 1.0 17 (13.4) 1
Smoking   0.69   
  Former smoker, n (%) 4 (40) 6 (30)  — —
  Current smoker, n (%) 0 0  — —
Chemotherapy   0.63   
  Neoadjuvant, n (%) 8 (80) 15 (75)  — —
  Adjuvant, n (%) 1 (10) 5 (25)  — —
Hormone therapy, n (%) 9 (90) 10 (50) 0.049§ — —
Previous breast radiation, n (%) 1 (10) 1 (5) 1.0 0 0.073
Clinical stage   0.49  —
  Stage 0, n (%) 0 0  —  
  Stage 1, n (%) 1 (10) 0  —  
  Stage 2, n (%) 6 (60) 12 (60)  —  
  Stage 3, n (%) 3 (30) 8 (40)  —  
  Stage 4, n (%) 0 0  —  
Pathological stage‡   0.48  —
  Stage 0, n (%) 0 1 (5)  —  
  Stage 1, n (%) 1 (10) 0  —  
  Stage 2, n (%) 6 (60) 9 (45)  —  
  Stage 3, n (%) 3 (30) 9 (45)  —  
  Stage 4, n (%) 0 0  —  
Receptor status      
  ER+, n (%) 10 (100) 14 (70) 0.074 — —
  PR+, n (%) 9 (90) 11 (55) 0.1 — —
  HER2+, n (%) 3 (30) 0 0.030§ — —
*All using Fisher’s exact test unless otherwise specified.
†t test.
‡One patient in the conventional cohort had a pathological complete response (pCR).
§P-values <0.05.
BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ER, estrogen receptor; HER2, human epidermal growth factor 
receptor 2; PR, progesterone receptor; PVD, peripheral vascular disease.
—, not available.
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communication and encourage early participation among 
all members of the multidisciplinary breast cancer team.
A custom bolus approach to PMRT, which involves 
close collaboration with the radiation oncology team, 
limits radiation delivery to the incision and the vascular 
pedicle in autologous reconstruction, thereby reducing 
potential for PMRT complications such as vascular injury, 
skin changes, fat necrosis, and delayed wound healing. 
Our patients who received custom bolus tended to have 
fewer skin changes, contour irregularities, skin flap necro-
sis, and volume loss than patients who received standard 
bolus. Although the use of custom bolus will likely reduce 
fat necrosis rates in autologous reconstruction moving for-
ward when routinely implemented, our fat necrosis rates 
were higher in the custom bolus population than in our 
institutional controls and other historical controls. We can 
attribute this to multiple factors: institutional, diagnostic, 
and patient related. First, institutional factors, including 
new faculty and strengthened relationships between de-
partments, has led to more rigorous follow-up, physical 
examination, and documentation of outcomes. This trans-
lates to increased detection of clinical outcomes and mor-
bidity, such as fat necrosis. Our institution also performed 
primarily pedicled TRAM flaps in the early portion of this 
study period, which in some studies have higher docu-
mented rates of fat necrosis.43,44 This is no longer the case; 
since 2011 almost all the autologous reconstructions we 
perform are deep inferior epigastric perforator free DIEP 
Table 2. Surgical Characteristics of Custom and Standard Bolus Patients
 
Custom Bolus 
(n = 10)
Standard Bolus 
(n = 20)
P-value
(Custom Bolus vs Standard 
Bolus)*
Mirzabeigi et al.
(n = 127)
P-value
(Custom Bolus vs Mirza-
beigi et al.)*
Mastectomy type   0.59  —
  Non-skin-sparing, n (%) 2 (20) 3 (15)  —  
  Skin-sparing, n (%) 5 (50) 7 (35)  —  
  Total skin-sparing, n (%) 3 (30) 10 (5)  —  
Incision type   0.33  —
  Inframammary, n (%) 2 (20) 4 (20)  —  
  Superior areolar, n (%) 0 5 (25)  —  
  Inferior periareolar, n (%) 4 (40) 5 (25)  —  
  Radial, n (%) 0 2 (10)  —  
  Other, n (%) 4 (40) 4 (20)  —  
Reconstruction   0.73  <0.001†
  Pedicle TRAM, n (%) 8 (80) 17 (85)  0  
  Free TRAM, n (%) 0 1 (5)  88 (69.3)  
  DIEP, n (%) 2 (20) 2 (10)  28 (22.0)  
  Other, n (%) 0 0  11 (8.7)  
Recipient vessel   1  0.23
  Internal mammary, n (%) 2 3  58  
  Thoracodorsal, n (%) 0 0  67  
  Other, n (%) 0 0  1  
*All using Fisher’s exact test.
†P-values <0.05.
DIEP, deep inferior epigastric perforator; TRAM, transverse rectus abdominis myocutaneous.
—, not available.
Table 3. Comparison of Specific Complications in Custom and Standard Bolus Patients with Those Reported by Mirzabeigi 
et al.
 
Custom Bolus 
(n = 10)
Standard Bolus 
(n = 20)
P-value
(Custom Bolus vs 
Standard Bolus)*
Mirzabeigi et al.
(n = 127)
P-value
(Custom Bolus vs 
Mirzabeigi et al.)*
Early complications      
  Flap loss, n (%) 0 0 1 2 (1.6) 1
  Cellulitis, n (%) 2 (20) 3 (15) 1 10 (7.9) 0.21
  Skin flap necrosis, n (%) 0 1 (5) 1 25 (19.7) 0.21
  Delayed wound healing, n (%) 4 (40) 4 (20) 0.38 62 (48.8) 0.75
Late complications      
  Volume loss, n (%) 1 (10) 3 (15) 1 29 (22.8) 0.69
  Contour deformity, n (%) 1 (10) 3 (15) 1 39 (30.7) 0.28
  Fat necrosis, n (%) 4 (40) 5 (25) 0.43 21 (16.5) 0.08
Nipple necrosis, n (%) 0 2 partial (10) 0.54 — —
Skin changes, n (%) 0 2 (10) 0.54 — —
Axillary cording/scarring, n (%) 2 (20) 7 (35) 0.67 — —
Revision surgery      
  Implants, n (%) 1 (10) 0 0.33 8 (6.3) 0.51
  Fat grafting, n (%) 0 0 1 13 (10.2) 0.60
  Breast liposuction, n (%) 1 (10) 3 (15) 1 9 (7.1) 0.54
  Local tissue rearrangement, n (%) 2 (20) 5 (25) 1 43 (33.9) 0.50
—, not available.
*All using Fisher’s exact test.
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flaps. Second, diagnosis of fat necrosis is subjective, varies 
considerably between clinicians, and is inconsistently doc-
umented. Comparing outcomes between different institu-
tions and historical literature is subjective,20 due to these 
inconsistencies. Finally, patient factors, including other 
risk factors for fat necrosis, such as obesity and smoking, 
as well as inconsistent follow-up and variable symptoms af-
fect the ability to detect and compare outcomes.44
Additionally, our sample sizes are small, which makes 
drawing definitive conclusions difficult. This is because 
in the past we seldom performed immediate autologous 
reconstruction in patients who required PMRT. Our phi-
losophy has changed though, and we believe autologous 
tissue flaps tolerate radiation better than mastectomy skin 
flaps over prosthetic devices, and consequently, are per-
forming more autologous reconstructions when PMRT is 
anticipated.
Another potential limitation of our study is its retro-
spective nature. Ideally, we would prospectively evaluate 
how different radiation protocols influenced postmastec-
tomy immediate autologous reconstruction. However, the 
feasibility of accomplishing this is limited by the fact that 
relatively few women who undergo immediate autologous 
reconstruction will require radiation therapy. Additionally, 
custom bolus is now the standard of care for our busiest 
radiation oncologist. Our current practice is to use custom 
bolus and targeted radiation delivery to all our immediate 
free flap breast reconstructions. With these changes, we 
are experiencing lower fat necrosis rates and fewer com-
plications in these individuals. Future research is directed 
toward evaluating aesthetic outcomes and complications in 
immediate autologous reconstruction versus delayed recon-
struction with tissue expanders after custom bolus PMRT.
Our 2 cohorts were separated chronologically: standard 
bolus was used earlier in the 10-year study period and cus-
tom bolus was used later. This creates potential confound-
ers and limits our ability to draw definitive conclusions. For 
instance, surgical technique may be improved over time, 
which may result in fewer complications. Additionally, 
more free flaps were performed later in the study period. 
These are better vascularized than pedicled flaps, and have 
less fat necrosis. Conversely, emphasizing the importance 
of clinical exam, documentation, and follow-up has led to 
increased detection and documentation of complications. 
The chronological separation may also benefit the study de-
sign in that the clear division in PMRT technique removes 
procedural selection bias, similar to what occurs in studies 
that compare types of autologous tissue reconstruction.43
Plastic surgeons and radiation oncologists must bal-
ance the concerns regarding technical delivery and long-
term toxicities of PMRT in the setting of immediate breast 
reconstruction27 with the prolonged patient discomfort 
in delayed reconstruction after PMRT. Radiation causes 
inflammatory changes to the microvasculature, causes 
microthrombi, and leads to vessel occlusion and athero-
sclerosis.45 Custom bolus has the potential to assuage these 
concerns. Additionally, this technique adapts with our 
changing surgical practice, as many centers now perform 
total skin-sparing or nipple-sparing mastectomies. Radia-
tion boost fields should target the chest wall, the area of Ta
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highest risk of recurrence, and away from the skin and 
mastectomy scar.11 Although our cohorts are small, we 
have 5-year follow-up data showing no difference in local 
or distant cancer recurrence rates between the 2 tech-
niques. Custom bolus allows the radiation oncologist to 
tailor skin and scar radiation exposure while providing ad-
equate dosage to the tissues at risk, thus not compromis-
ing oncologic safety. This offers improved nipple/areola 
complex survival and aesthetics. The use of custom bolus 
can be achieved by any institution, and there are a variety 
of ways it may be performed, with our description just 1 
option. Another option is to use brass mesh bolus, which 
also conforms to the shape of the reconstruction.46
We propose that plastic surgeons advocate for custom 
bolus as their preferred method of PMRT because this 
method has promising preliminary results on patient out-
comes and would facilitate greater collaboration between 
specialties. Custom bolus is easily fabricated, cost-effective, 
and placement is straightforward and reproducible. The 
improved dose homogeneity created with the individual-
ized, customized contoured surface bolus is hypothesized 
to account for improved aesthetic outcomes.28 This tech-
nique allows the radiation oncologist to recognize, plan, 
and avoid the mammary vessels and anastomoses with radi-
ation beams. Additionally, by avoidance of radiation to the 
skin, scar, and internal mammary nodes, reconstruction 
complications are minimized.28 Although custom bolus re-
quires time investment from both the plastic surgery and 
radiation oncology teams, and institutional support for the 
added costs and infrastructure (designing molds, software 
for delivery, and employing a physicist), we believe its po-
tential for superior outcomes are worth the investment.
Prospective research is under way at our institution to 
provide objective means of recording postoperative out-
comes and complications to better understand the relation-
ship between immediate autologous breast reconstruction 
and custom bolus PMRT. We are considering tissue sam-
pling, as well as noninvasive imaging, as a way to quantify 
outcomes with this technique. Additionally, we are incor-
porating BREAST-Q as part of every breast cancer patient’s 
follow-up to document patient reported outcomes. Further-
more, we are working with the radiation oncology depart-
ment to establish guidelines for a more uniform approach 
to postautologous reconstruction radiation therapy.
CONCLUSIONS
Custom bolus radiation therapy offers individualized 
PMRT that can tailor radiation to the skin, incision, and 
vascular pedicle in autologous tissue breast reconstruc-
tion. In our patients, custom bolus resulted in fewer skin 
changes and decreased volume loss. With larger patient 
populations and better standardization of outcomes re-
porting, we anticipate more support for this novel method.
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